Cha Vaccine Research Institute Co., Ltd., a research-oriented biotechnology company, researches and develops a range of vaccine products targeting infectious and chronic diseases. Its product pipeline includes HBV vaccine that is in Phase IIb planning for the prevention of hepatitis B; Adjuvanted HBV vaccine that is in Phase I/IIa for the treatment of chronic hepatitis B; and VZV Vaccine, which is in pre-clinical planning stage for the prevention of Herpes Zoster. The company also develops influenza vaccine, recombinant MBL, TB vaccine, and cancer vaccine. Cha Vaccine Research Institute Co., Ltd. was founded in 2000 and is headquartered in Seongnam, South Korea.
Metrics to compare | 261780 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship261780PeersSector | |
---|---|---|---|---|
P/E Ratio | −7.0x | −4.4x | −0.5x | |
PEG Ratio | 0.01 | −0.06 | 0.00 | |
Price/Book | 3.2x | 1.9x | 2.6x | |
Price / LTM Sales | −7,952,112,816.0x | 4.8x | 3.2x | |
Upside (Analyst Target) | - | 0.0% | 41.4% | |
Fair Value Upside | Unlock | 13.2% | 6.0% | Unlock |